GENELINK Featured at WallStreetCorner
August 25, 2004

MARGATE, NJ--(BUSINESS WIRE)—August 25, 2004 -- GeneLink BioSciences, Inc.
(OTC BB: GNLK - News) announced it is featured in “Larry Oakley’s Stock Pick” editorial column at www.WallStreetCorner.com.

Oakley’s introduction: “I interviewed CEO John DePhillipo (on 8/23/2004) to get a feel for the timing of revenue flow from GNLK’s various associations for the distribution of its “dermagenetics” tests & products. The first arrangement began a year ago, & the cash flow has now begun. I see it growing at a reasonably rapid pace now that it is underway. There are several other arrangements in the works, and John feels at least two of them will begin revenue flow during Q1 2005.”

In his conclusion, Oakley says: “GNLK is a sleeper. It closed at $0.28 on 8/23/2004 – a great opportunity to get a piece of the action at what I see as a very low price. There were 31,124,999 shares out at 6/30/2004, & the 52-week range is $0.27 - $0.85.

About GeneLink: GeneLink BioSciences, Inc., since 1994, created the World's First Family Centered DNA Bank and Hereditary Genetic Information Service. The Genetics Bioscience company is a pioneer and leading provider of DNA tests created to facilitate "genetically guided" health, beauty and wellness products. The company both markets and licenses the GeneLink Nutragenetic Profile™ and its Dermagenetics® proprietary tests to the $1.4 trillion cosmetics, nutritional supplement and healthcare industries. For more information about GeneLink, visit its Web site at www.genelink.info.

About WallStreetCorner: Formed six years ago as a venue for the Conservative Speculator newsletter, published since 1987, WallStreetCorner -- including Conservative Speculator and Oakley's "Stock Pick," "Opinion," "Comment," and “Bold Ventures” editorial columns -- is now regularly read by investors in 78 countries.

WallStreetCorner has been compensated to prepare the GNLK profile.

This press release contains certain forward-looking statements within the meaning of section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. With the exception of historical information contained herein, the matters discussed in the press release involve risk and uncertainties. Actual results could differ materially from those expressed in any forward-looking statement. GNLK disclaims any intention or obligation to revise any forward-looking statements, whether as a result of new information, future developments or otherwise.

GeneLink Contact:
Philip DuBois, Investor Relations 877-386-4649 or 757-229-0666
Email: duboisconsultgp@cox.net

SOURCE: GeneLink BioSciences, Inc.